In Brief: Cordis
This article was originally published in The Gray Sheet
Cordis: Firm's three-dimensional electrophysiology mapping technology, acquired through an August licensing agreement with Biosense ("The Gray Sheet" Aug. 7, In Brief), "has been successfully tested in initial human clinical cases" in Israel, Cordis says. "A three-dimensional reconstruction" of the right atrium's electrical activity with 35 data points were successfully produced in two patients, the firm says. The maps were produced within five minutes, the company states, noting that "with conventional electrophysiology, such a mapping procedure could take as much as two hours to perform." Additional trials slated for the next several weeks will "involve mapping of atrial fibrillation and ventricular tachycardias," Cordis says...
You may also be interested in...
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.